Unopposed oestrogen is responsible for approximately 80% of all the endometrial cancers. The relationship between unopposed oestrogen and endometrial cancer was indicated by the increase in the number of endometrial cancer cases due to the widespread use of oestrogen replacement therapy. Approximately 30% of the endometrial cancer patients have mutations in the Wnt signalling pathway. How the unbalanced ratios of ovarian hormones and the mutations in Wnt signalling pathway interact to cause endometrial cancer is currently unclear. To study this, we have developed a uterine epithelial cell-specific inducible cre mouse model and used 3D in vitro culture of human endometrial cancer cell lines. We showed that activating mutations in the Wnt signalling pathway for a prolonged period leads to endometrial hyperplasia but not endometrial cancer. Interestingly, unopposed oestrogen and activating mutations in Wnt signalling together drive the progression of endometrial hyperplasia to endometrial cancer. We have provided evidence that progesterone can be used as a targeted therapy against endometrial cancer cases presented with the activating mutations in Wnt signalling pathway.
Introduction
Endometrial cancer is the most common gynaecological cancer, with approximately 76 000 deaths and 318 000 new diagnoses, each year (1) . Endometrial adenocarcinoma originates from the epithelial lining of the endometrium (2) . Based on histology, endocrine and clinical features, endometrial cancer can be divided into two types-type 1 and type 2 (3). Type 1 endometrial cancer is caused by unopposed oestrogen and affects nearly 80% of all endometrial cancer patients (3) . In contrast, type 2 endometrial cancer is oestrogen independent, which affects postmenopausal women and account for rest of the 20% of endometrial cancer patients (3) .
Both types 1 and 2 endometrial cancers are associated with distinct mutations in different molecular pathways. Type 1 endometrial cancer is associated with mutations in PTEN, KRAS, CTNNB1 and DNA repair genes, whereas type 2 endometrial cancer harbors mutations in TP53, Her2/neu and p16 (4, 5) . Despite such heterogeneity, currently, both types of endometrial cancers are treated with the same approach which includes surgery followed by chemotherapy and radiotherapy (2) .
Approximately 30-85% of type 1 endometrial cancer cases show nuclear accumulation of β-catenin in the epithelium, indicative of active Wnt signalling pathway (6, 7) . The genetic mutations affecting the Wnt/β-catenin signalling pathway are mostly found in young females with more aggressive forms of endometrial adenocarcinoma (8) (9) (10) (11) . These patients have worst prognosis and poor overall survival rate (11) . Thereby, it is important to understand the endometrial changes leading to the initiation of endometrial cancer. Previous studies have shown that dysregulation of β-catenin is responsible for progression, but not initiation of the disease (12) . However, these studies were carried out using transgenic mouse models, where the oncogenic recombination occurs in early stages of development leading to defective uterine organogenesis, as compared to genetic mutations in humans that are acquired in later life. Although it is known that type 1 endometrial cancer is hormone-driven, the mechanism underlying the interaction between hormones and the Wnt signalling pathway in endometrial cancer is still unclear.
In this study, using an epithelial-specific inducible-cre mouse model and 3D in vitro system, we have shown that sustained activation of Wnt/β-catenin drives the development of endometrial hyperplasia, a precursor to endometrial cancer (13) . Furthermore, we have shown that oestrogen acts in synergy with Wnt signalling to transform endometrial hyperplasia into endometrial cancer and provided evidence to support that hormone therapy could be used as a potential treatment for endometrial cancer driven by the activation of Wnt signalling.
Hormone treatment
Hormone treatments were performed as described previously (19) . Sixweek-old Ctnnb1 ex3 cko mice were ovariectomised and administered with doxycycline for 4 weeks to induce recombination. Two weeks post-ovariectomy, mice were subcutaneously implanted with hormone pellets of 17-β-oestradiol (90-day time release; 0.72 mg per pellet) or 17-β-oestradiol and progesterone (0.72 and 100 mg per pellet, respectively; Innovative Research of America, FL). Mutant ovariectomised mice treated with doxycycline and no hormone treatment were used as controls. Few of the mice developed abnormal peritoneal swelling and therefore, all the mice in this experiment were euthanised and tissues were collected 46 days posthormone pellet insertion. Similar treatment regimen was also performed on the control ovariectomised mice to evaluate the effect of long-term (90 days) hormone treatment on uterus. Uteri collected were fixed in 4% paraformaldehyde overnight at 4°C.
Tissue processing, IHC and immunofluorescence
Human endometrial cancer samples were collected from the Hunter Cancer Tissue Biobank using a protocol approved by the Institutional Human Research Ethics Committee at the University of Newcastle. Immunostaining was performed as described previously (19, 20) .
Paraformaldehyde-fixed samples were processed and paraffin sections of 4 µm thickness were prepared. The tissue sections were incubated with the following antibodies: β-catenin (1:200, BD biosciences, NJ), Ki67 (1:800, Abcam, MA), CK8 (1:250, Developmental Studies Hybridoma Bank, IA), Oestrogen receptor α (ERα, 1:200, Santa Cruz Biotechnology), Phospho S118-oestrogen receptor α (1:200; Abcam, MA), Progesterone receptor (PR, 1:300, Santa Cruz Biotechnology). Alexa fluor secondary antibodies (1:250, Jackson Laboratories) were used to detect the primary antibodies. Same exposure time and gain were used to obtain immunofluorescence images for both mutants and controls. For immunohistochemistry, both mutant and control slides were exposed to 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich) for the same time. TUNEL assay was performed according to the manufacturer's instructions (Millipore). Olympus DP72 microscope was used to obtain the images. Ki67 quantitation was performed using Immunoratio web application (21) .
Quantitative real-time PCR
Quantitative real-time PCR was performed as previously described (15) . Briefly, total RNA was isolated from 10-week-old doxycycline-treated Ctnnb1 ex3 cko and control uteri (N = 3, in diestrus phase of the oestrus cycle) and each hormone-treated Ctnnb1 ex3 cko uterus (N = 3 per each) using RNeasy® Micro kit (Qiagen, VIC, Australia). cDNA was synthesized from total RNA using RT 2 First Strand Kit (Qiagen). QPCR was then performed using RT 2 SYBR Green ROX qPCR Mastermix (Qiagen) on ABI 7900 HT FAST (Applied Biosystems, CA). With the exception of Tcf-1, all reactions were run under the following conditions: 50°C for 2 min, 95°C for 10 min, 95°C for 15 s and 60°C for 1 min/40 cycles (Tcf-1 includes an additional step for annealing, 55°C for 1 min/40 cycles). Expression of the target genes was normalized to the experimental Ct value of the housekeeping gene (Gapdh). Gene expression was then analysed by the ∆∆Ct method. Analysis of the Wnt signalling pathway was performed using RT 2 Profiler PCR Array kit (Qiagen) as described by us in (22) .
Cell culture
Eight-well chambered plate (Corning Inc.) were coated with a thin layer of BD Matrigel™ (BD Biosciences). Ishikawa (passage 33-35; Sigma-Aldrich) and Hec1A (passage 32-34; ATCC) cells were seeded at 10 000 cells per well and cultured for 8 days in Minimum Essential Medium with Earle's Balanced Salts solution media (Sigma-Aldrich) and McCoys 5A media (Sigma-Aldrich) supplemented with 3% BME, respectively. Media was changed every 2-3 days. The cells were treated with oestrogen (100 nM; Sigma-Aldrich) and progesterone (250 nM; Sigma-Aldrich) from day 1 of the experiment for the entire duration of the experiment. Ishikawa and Hec1A cell lines were purchased in 2012 from Sigma and American Type Culture Collection, respectively, and validated using short tandem repeat profiling (The Australian Genome Research Facility). The short tandem repeat profiles of these cells were same as the original cells. We perform short tandem repeat profiling (every 6-month interval; last tested 06/17) and mycoplasma testing (every 3-month interval, MycoAlertTM Plus Mycoplasma detection kit, Lonza, MD) for the validation of these cell lines and quality control of cell culture conditions.
Western blot analysis
Western blot analysis was performed as described previously by us in (19) . Briefly, Ishikawa and Hec1A cells were cultured in a six-well plate (Corning, Sigma, Australia) for 2-3 days. Protein was isolated using RIPA buffer. Equal concentrations of protein extracts from these two cell lines were run on 10% SDS-PAGE gel. Primary antibodies against total β-catenin (1:1000; Cell Signalling Technology, MA) and GAPDH (1: 10 000; Cell Signalling Technology) were used. Horseradish peroxidase-conjugated secondary antibodies were used to detect the primary antibodies (Jackson laboratories, PA). Densitometric analysis was performed using ImageJ (National Institute of Health).
Fertility and Implantation analysis
Fertility and implantation studies were performed as described previously (22) . Briefly, 6 weeks old Ctnnb1 ex3 cko and control female mice were administered with 1 mg/ml doxycycline in drinking water supplemented with 5% sucrose for 3 weeks before mating them with wild-type males
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progesterone receptor PCR polymerase chain reaction of known fertility. Copulatory plugs were observed, and day of plug was considered as day 1 of pregnancy. Fertility analysis was carried out for a period of 6 months.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6.0 Software. Data are expressed as mean ± SEM. To determine statistical significance, we performed the Student t test for comparing two groups and analysis of variance for multiple group comparisons, using GraphPad Prism 7.02 software, with a P-value of <0.05 considered significant.
Results
Generation of a mouse model with constitutive activation of β-catenin in uterine epithelium
One of the major factors driving endometrial cancer is activating mutations in the Wnt signalling pathway in the uterine epithelium (23) . However, the lack of availability of mouse models with inducible cre specifically in the uterine epithelium has resulted in poor understanding of the disease. Therefore, to elucidate the role of active Wnt signalling, we generated a triple transgenic mouse model with Pax8, a uterine epitheliumspecific promotor, driven tetracycline-controlled transactivator cre (tetO-cre) to delete exon 3 of Ctnnb1 (β-catenin; Figure 1A ). The exon 3 of Ctnnb1 has the sites for the phosphorylation by a destruction complex known as APC complex (Adenomatous polyposis coli complex). The phosphorylated form of β-catenin is recognised by β-TrCP, a component of E3 ubiquitin ligase complex, leading to the ubiquitination and degradation of β-catenin (24) . Administration of doxycycline to this mouse model results in the deletion of exon 3 from Ctnnb1 thereby inhibiting the phosphorylation and ubiquitination of β-catenin, leading to cytoplasmic and nuclear accumulation of excessive β-catenin protein (25) . Recombination PCR was performed to confirm the successful recombination of Ctnnb1 allele in the mutant uteri. DNA was isolated from the control and mutant uteri and a 700 bp amplified product of the recombined allele of Ctnnb1 was only found in the mutant uteri ( Figure 1B ). DNA isolated from the mouse tail was used as a negative control ( Figure 1B ). To confirm the specificity of our mouse model, we generated another mouse model where LC1 rtta;tetocre mice were bred with LacZ fl/fl mice to obtain LacZ cko/+ ( Figure 1C ). β-galactosidase staining confirmed that the recombination occurs specifically in the uterine epithelium ( Figure 1C ). Furthermore, immunostaining for β-catenin confirmed the nuclear and cytoplasmic accumulation of β-catenin protein in uterine epithelium of doxycyclinetreated mutant uteri compared to the controls ( Figure 1D 
Constitutive activation of β-catenin in uterine epithelium leads to endometrial hyperplasia but no cancer
To determine if sustained activation of Wnt signalling in the uterine epithelium is sufficient to cause endometrial cancer, 6-week-old Ctnnb1 ex3 cko mice were administered with doxycycline for 4 weeks (Figure 2A ). Histological analysis of the mutant uteri from these mice revealed increased epithelial to stromal ratio, which is a characteristic feature of hyperplasia, a precursor of endometrial cancer ( Figure 2B-D) . The mutant uteri showed deeper epithelial invaginations into the stroma compared to control uteri (Figure 2E and F; N = 3 per group). Furthermore, there was a significant increase in the number of endometrial glands in mutant uteri compared to controls ( Figure 2G ; N = 3 per group). Immunostaining for a marker for proliferating cells, Ki67, revealed increased epithelial proliferation in the uterine epithelium ( Figure 2H and I) . To determine if constitutive activation of β-catenin affects the expression of ovarian hormone receptors, we performed immunohistochemistry for ovarian steroid hormone receptors, ERα and PR. No difference in expression of either ERα or PR was observed between the mutant and control mice uteri ( Figure 2J-M) . However, the expression of phosphorylated ERα was increased in the mutant endometrial epithelium compared to controls (Supplementary Figure 2 , available at Carcinogenesis Online).
To examine if long-term constitutive activation of the Wnt/β-catenin signalling pathway is sufficient to cause endometrial cancer, mutant mice were administered doxycycline for 12 weeks ( Figure 3A ). Histological analysis of uteri from these mice revealed endometrial hyperplasia in mutants but not controls (N = 3 per group; Figure 3B and C). However, endometrial hyperplasia did not progress to endometrial cancer in any of the mutant mice examined in this study. Nuclear and cytoplasmic accumulation of β-catenin in the mutant uteri confirmed sustained activation of Wnt signalling ( Figure 3D-G) . Immunostaining for Ki67 revealed significant increase in the number of proliferating cells in the mutant uterine epithelium as compared to the control uterine epithelium ( Figure 3H-J) . Therefore, these results reveal that the constitutive activation of Wnt/β-catenin signalling exclusively in the uterine epithelium leads to endometrial hyperplasia but is insufficient to cause endometrial cancer.
Reduced fertility following hyperactivation of β-catenin in the uterine epithelium
To determine if constitutive activation of the Wnt/β-catenin signalling affects uterine functions, we treated Ctnnb1 ex3 cko female mice with doxycycline for 3 weeks before breeding them with wild-type males of known fertility for 6 months. The mutant females were subfertile-only one Ctnnb1 ex3 cko female produced pups and the litter size was reduced compared to controls (Table 1) . To exclude ovarian abnormality as a potential cause of subfertility, histological analysis of ovaries was performed. Ovarian follicles and corpus luteum were present in both mutant and control ovaries (Supplementary Figure 3, available at Carcinogenesis Online). This was expected as LC1cre is not expressed in the ovary (19) . Therefore, these results suggest that sustained activation of the Wnt/β-catenin signalling in uterine epithelium leads to reduced fertility in mice. To further dissect the defect in fertility, we collected uteri from the timed mated females at dpc 5.5. Compared to controls (N = 5/5; 100%), implantation sites were only observed in 25% of Ctnnb1 ex3 cko females (N = 1/4). Collectively, these results support that abnormal activation of Wnt/β-catenin signalling in the mouse uterine epithelium severely compromises fertility.
Synergistic actions of Wnt signalling and unopposed oestrogen leads to endometrial cancer development
Type 1 endometrial cancer is hormone dependent, caused by prolonged exposure to unopposed oestrogen (26) . Activating mutations in the Wnt/β-catenin signalling pathway members are mainly found in the uterine epithelium of endometrial cancer patients (6) . To determine the relationship between constitutive activation of Wnt signalling in the uterine epithelium and ovarian steroid hormones, Ctnnb1 ex3 cko mice were administered doxycycline at 6 weeks of age to induce recombination. These females were then ovariectomized 2 days post-initiation of doxycycline treatment ( Figure 4A) . The mice were then allowed to rest for 14 days to clear endogenous hormones. Following this, slow-releasing hormone pellets of E2 or E2+P4 were subcutaneously inserted. Hormone treatment continued for 46 days before the tissues were collected. As expected, E2-treated Ctnnb1 However, we were unable to chase these mutant mice for more than 46 days to observe further progression of metastatic growth because of kidney problems (Supplementary Figure 5 , available at Carcinogenesis Online).
During the proliferative phase of the menstrual cycle, when the oestrogen levels are high, increased nuclear expression of β-catenin was observed in human endometrium, which is suggestive of active Wnt signalling (23) . The level of β-catenin decrease during the secretory phase when the proliferative effect of oestrogen is counterbalanced by progesterone (23) . Thus, suggesting that changes in the levels of these ovarian steroid hormones regulate Wnt signalling. To determine if progesterone inhibits endometrial cancer developed due to activation of Wnt/β-catenin signalling, we treated our mouse model with slow release pellets of oestrogen with progesterone. A significant decrease in the number of glands in the E2+P4 group was observed as compared to the E2-treated group (N = 5; Figure 4D and G). Interestingly, histological analysis of the mutant uteri in the control group (without hormone treatment) showed the absence of endometrial hyperplasia (N = 3; Figure 4B and E). Importantly, the combination of oestrogen and progesterone treatment significantly reduced the number of glands compared to the E2-treated group ( Figure 4C-H) .
To further determine the synergistic role of β-catenin and oestrogen, control mice were ovariectomised and inserted with slow releasing hormone pellet for 90 days. Histological analysis of these mice uteri revealed the presence of endometrial hyperplasia in the E2-treated mice but not in E2+P4-treated mice, which were comparable to untreated controls (Supplementary Figure 6A -C, available at Carcinogenesis Online). Immunostaining for β-catenin showed increased nuclear/cytoplasmic accumulation of β-catenin in the uterine epithelium of the E2-treated 
Progesterone mediates the inhibition of endometrial cancer through downregulation of Wnt/β-catenin signalling
To examine if progesterone mediates the inhibition of endometrial cancer through suppression of Wnt/β-catenin signalling, we assessed the downstream components of the Wnt signalling pathway in mice uteri treated with ovarian hormone pellets. Immunostaining for β-catenin confirmed the over-expression of β-catenin in the uterine epithelium of control and E2-treated mutant mice (Figure 5A-C) . In comparison, decrease in the nuclear/cytoplasmic accumulation of β-catenin in the E2+P4-treated mice was observed, along with the patches of epithelial cells having only membranous expression of β-catenin ( Figure 5A-C) . These results were further confirmed by qPCR analysis that showed a 5-fold increase in β-catenin expression in the E2-treated group, whereas, 0.5-fold downregulation was observed in the E2+P4 treated group as compared to the control group ( Figure 5D ). Furthermore, significant decrease in Tcf1 expression was observed in the E2+P4-treated group as compared to the E2-treated and control group ( Figure 5E-H) . These results suggest that progesterone inhibits canonical Wnt signalling, which is stimulated by the E2 treatment.
To determine whether the reduction in pathological lesions in the E2+P4-treated group was due to reduced proliferation or increased apoptosis, we performed immunostaining for Ki67, a marker for cell proliferation, and TUNEL assay, to detect apoptotic cells. As expected, a significant increase in the number of proliferating cells was observed in the uterine epithelium of mutant mice treated with E2 as compared to the E2+P4-treated group and controls ( Figure 5I-L) . Significant reduction in the number of apoptotic cells was observed in the uterine epithelium of the E2+P4 and E2-treated groups compared to controls ( Figure 5M-P) . This is consistent with previous observations that E2/E2+P4/P4 treatment suppresses cell death of mouse uterine epithelium (28) . To examine if progesterone suppresses the endometrial cancer through ovarian hormone receptors, we performed immunostaining for ERα and PR. No difference in the ERα and PR expression in all three groups ( Figure 5Q-V) .
To confirm the effect of hormone treatment in reversing the endometrial cancer phenotype, we examined two well-established endometrial cancer cells, Hec1A (harbour mutations in CTNNB1, KRAS and PIK3CA) and Ishikawa (harbour mutations in PIK3R1 and PTEN). These are moderately well differentiated and well differentiated adenocarcinoma cell lines, respectively. Both of these cell lines express ERα and PR (29, 30) . Western blot analysis was performed to determine the endogenous levels of β-catenin protein in these cell lines. Hec1A cells harbor mutations in β-catenin and consistently showed higher levels of β-catenin protein compared to Ishikawa cells (Fig. 6A ). These cell lines were then cultured in BME and hormone treated with E2, P4 and E2+P4. The cells cultured without the addition of hormones were used as control group. In 3D culture, Ishikawa cells formed well-rounded glandular colonies, similar to normal endometrial cells (31, 32) , whereas, Hec1A cells formed disorganised non-spheroid colonies, representing a more cancer-like state (31, 32) (Figure 6B ). Interestingly, Hec1A cells formed significantly more number of non-spheroid colonies in presence of E2. P4 treatment of these cells formed well-rounded glandular colonies ( Figure 6B-E) . Furthermore, E2 treatment of these spheroids leads to increase in the spheroid perimeter as compared to E2+P4, P4 and control groups ( Figure 6D and E). Treatment with E2+P4 and P4 alone results in the formation of smaller and well-rounded spheroids ( Figure 6B-E) . Examination of the Ishikawa 3D spheroids also revealed increased spheroid size in the E2-treated group while the spheroids size in the E2+P4 group was comparable to the control group (Supplementary Figure 7 , available at Carcinogenesis Online). However, compared to the Hec1A 3D spheroids, Ishikawa spheroids were more organized and maintained proper round morphology, which was similar to normal human endometrium (31, 32) . Examination of β-catenin expression revealed decrease in the level of β-catenin protein in P4-treated group compared to E2-treated group (Supplementary Figure 8 , available at Carcinogenesis Online). Collectively, these results further support the inhibitory effects of progesterone treatment on endometrial cancer cells.
Discussion
The relationship between unopposed oestrogen and type 1 endometrial cancer was established in the early 1970s due to an increase in the number of endometrial cancer cases reported in women using oestrogen replacement therapy (33) . Type 1 endometrial cancer is a disease of pre-/peri-/post-menopausal females (2) . Perimenopause, or the transition state, is considered a 'window of risk' due to the presence of unopposed oestrogen, as increased irregularities and anovulatory cycles lead to inadequate levels of progesterone (34) . Therefore, females experiencing perimenopause have relatively high serum levels or increased secretion of oestrogen (34) . A recent study has found that unopposed oestrogen alone drives endometrial hyperplasia, a precursor to endometrial cancer (35) . In addition, various studies have identified genetic mutations in type 1 endometrial cancer, mainly in PTEN, CTNNB1, KRAS and DNA repair genes (4), which suggests that unopposed oestrogen and the genetic mutations together lead to progression of endometrial hyperplasia to endometrial cancer. However, it is currently unclear how unbalanced hormone ratios and genetic mutations together lead to the development and progression of endometrial hyperplasia into endometrial cancer. In this study, we have shown that sustained activation of Wnt/β-catenin signalling for the chronic period does not progress to endometrial cancer. However, the constitutive activation of the Wnt/β-catenin pathway in the uterine epithelium in the presence of unopposed oestrogen results in endometrial cancer.
Progesterone has been used as a therapeutic agent in the treatment of young females suffering from endometrial adenocarcinoma and is able to restore fertility (36, 37) . However, the success of hormone therapy to treat endometrial cancer had been debatable as progesterone treatment occasionally fails in patients with ER/PR +ve tumours but is successful in ER/PR -ve tumours, thereby suggesting that progesterone acts by different mechanisms to suppress endometrial cancer (38) . Therefore, identification of progesterone-responsive tumours is required for more successful application of hormone therapy. In our study, we have shown that the oestrogen treatment increases the level of β-catenin, a downstream target of the Wnt signalling pathway, and progesterone treatment decreases the β-catenin levels ( Figure 5 ), suggesting that ovarian hormones regulate the Wnt signalling pathway. Interestingly, a recent study has found that dysregulation of the Wnt/β-catenin pathway is predominant in young endometrial cancer patients with worse progression-free survival and poor survival rate (11) . Collectively, our findings suggest that progesterone acts by suppressing the Wnt signalling, which provides the likely explanation for the success of hormone therapy in the younger patients.
Wnt signalling pathway members play an important role during the development and function of the uterus (39, 40) . Previous studies from our lab and others have shown that the dysregulation of the Wnt signalling, in the uterus leads to the development of endometrial hyperplasia and cancer. Constitutive activation of β-catenin in the uterus, using progesterone receptor-cre (Pgr cre ), leads to the development of endometrial hyperplasia and changes the nature of uterine epithelium. qPCR analysis confirmed a significant increase in the β-catenin and Tcf1 expression in oestrogen-treated group compared to controls, while, progesterone treatment had an opposite effect (D, H). Ki67, a marker of cell proliferation, was increased in the uterine epithelium of oestrogen-treated group (N = 5) compared to the oestrogen and progesterone-treated group (N = 5; I-L). Detection of apoptotic cells using TUNEL assay showed a significant decrease in the number of apoptotic cells (arrowheads) in E2+P4 and E2-treated group compared to control group (M-P). No change in the expression of ERα and PR was observed among different treatment groups (Q-V). Data is represented as mean ± SE (*P < 0.05, **P < 0.005, ****P < 0.0001). Bar: 50 um.
epithelium from columnar to pseudostratified epithelium (41) . Pseudostratified epithelium is a characteristic of the vaginal epithelium, suggesting homeotic transformation in the uterus leading to the change in the epithelial fate. The change in the epithelial fate might be due to the use of Pgr cre which results in recombination in prepubertal mice when the uterus is not fully developed in all uterine compartments, resulting in the changes in the epithelial nature due to alterations in the stromal-epithelial crosstalk. In our study, we did not observe any abnormal changes in the epithelial cell fate (Fig 2) . Furthermore, using anti Mullerian hormone receptor2-cre (Amhr2-cre), we have previously shown that dysregulation of the Wnt/β-catenin signalling in the stroma and myometrium results in the development of the endometrial stromal sarcomas and uterine leiomyomas (40) . Analysis in the human stromal sarcomas and leiomyosarcomas tissue samples have shown increased expression of β-catenin in the stroma (42) . Collectively, these studies emphasise the significance of the Wnt signalling in different uterine compartments to maintain uterine homeostasis. As endometrial cancer originates from the epithelium and is a disease of pre-/post-menopausal females, in this study using an inducible cre system, we have shown that the epithelialspecific constitutive activation of Wnt signalling in adult mice leads to the development of endometrial hyperplasia. The phenotype observed in our model mimics human endometrial hyperplasia, proving our model to be suitable for studying the mechanisms involved in endometrial cancer development. In addition, since endometrial hyperplasia and cancer is a disease of peri/postmenopausal women, using this model system gives us advantage to activate the cre in adult stages when the uterus is fully developed and mature. To our knowledge, this model system best mimics the human disease in terms of physiological/ biological timeline. Previous studies have mainly used Amhr2-cre and Pgr-cre to study the endometrial cancer which induce recombination around E-15.5 and dpn 10, respectively, primarily affecting the uterine development (43, 44) . Therefore, the phenotypes observed in these mouse models was not true reflection of human endometrial disease.
In conclusion, we have shown that the dysregulation of Wnt/β-catenin signalling in the uterine epithelium along with unopposed oestrogen drives the progression of endometrial cancer from endometrial hyperplasia. Progesterone mediates the inhibition of endometrial cancer by suppressing Wnt signalling pathway, suggesting hormone therapy can successfully be used to treat females suffering from endometrial cancer due to dysregulation of the Wnt/β-catenin signalling pathway.
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